Cargando…

Dual-phase [18F]florbetapir in frontotemporal dementia

PURPOSE: The PET tracer [18F]florbetapir is a specific fibrillar amyloid-beta (Aβ) biomarker. During the late scan phase (> 40 min), it provides pathological information about Aβ status. Early scan phase (0–10 min) can provide FDG-‘like’ information. The current investigation tested the feasibili...

Descripción completa

Detalles Bibliográficos
Autores principales:	Asghar, Michael, Hinz, Rainer, Herholz, Karl, Carter, Stephen F.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2018
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6333719/ https://www.ncbi.nlm.nih.gov/pubmed/30569187 http://dx.doi.org/10.1007/s00259-018-4238-2

Ejemplares similares

[18F]Florbetapir positron emission tomography: identification of muscle amyloid in inclusion body myositis and differentiation from polymyositis
por: Lilleker, James B, et al.
Publicado: (2019)

Radiation dosimetry of florbetapir F 18
por: Joshi, Abhinay D, et al.
Publicado: (2014)

[(18)F]Florbetapir PET/MR imaging to assess demyelination in multiple sclerosis
por: Carotenuto, Antonio, et al.
Publicado: (2019)

Pilot Study of F18-Florbetapir in the Early Evaluation of Cardiac Amyloidosis
por: Sperry, Brett W., et al.
Publicado: (2021)

Quantification of [(18)F]florbetapir: A test–retest tracer kinetic modelling study
por: Golla, Sandeep SV, et al.
Publicado: (2018)

Operationalizing the centiloid scale for [(18)F]florbetapir PET studies on PET/MRI
por: Coath, William, et al.
Publicado: (2023)

Extracardiac (18)F-florbetapir imaging in patients with systemic amyloidosis: more than hearts and minds
por: Wagner, T., et al.
Publicado: (2018)

(18)F-florbetapir PET as a marker of myelin integrity across the Alzheimer’s disease spectrum
por: Moscoso, Alexis, et al.
Publicado: (2021)

(18)F-Flortaucipir in TDP-43 associated frontotemporal dementia
por: Smith, R., et al.
Publicado: (2019)

Lacrimal gland uptake on F-18 florbetapir amyloid positron emission tomography scan
por: Itani, Malak, et al.
Publicado: (2017)

(18)F-MK-6240 tau-PET in genetic frontotemporal dementia
por: Levy, Jake P, et al.
Publicado: (2021)

Florbetapir F 18 amyloid PET and 36-month cognitive decline:a prospective multicenter study
por: Doraiswamy, P M, et al.
Publicado: (2014)

Using PET with (18)F-AV-45 (florbetapir) to quantify brain amyloid load in a clinical environment
por: Camus, V., et al.
Publicado: (2012)

PET imaging of 18F-florbetapir in cognitively impaired individuals: Lack of activity within the cerebellar cortex
por: Meyer, Michael A., et al.
Publicado: (2018)

(18)F-florbetapir PET/MRI for quantitatively monitoring demyelination and remyelination in acute disseminated encephalomyelitis
por: Zhang, Min, et al.
Publicado: (2019)

Hybrid (18)F-florbetapir PET/MRI for assessing myelin recovery in GFAP-A patients
por: Meng, Huanyu, et al.
Publicado: (2022)

(18)F-THK5351 PET Imaging in the Behavioral Variant of Frontotemporal Dementia
por: Nam, Gijin, et al.
Publicado: (2018)

Spill-in counts in the quantification of (18)F-florbetapir on Aβ-negative subjects: the effect of including white matter in the reference region
por: López-González, Francisco Javier, et al.
Publicado: (2019)

Application of Haralick texture features in brain [(18)F]-florbetapir positron emission tomography without reference region normalization
por: Campbell, Desmond L, et al.
Publicado: (2017)

Repeatability of parametric methods for [(18)F]florbetapir imaging in Alzheimer’s disease and healthy controls: A test–retest study
por: Verfaillie, Sander CJ, et al.
Publicado: (2020)

Tracer‐specific reference tissues selection improves detection of (18)F‐FDG, (18)F‐florbetapir, and (18)F‐flortaucipir PET SUVR changes in Alzheimer's disease
por: Li, Yanxiao, et al.
Publicado: (2022)

A consecutive case series experience with [(18) F] florbetapir PET imaging in an urban dementia center: impact on quality of life, decision making, and disposition
por: Mitsis, Effie M, et al.
Publicado: (2014)

(18)F-flortaucipir (AV-1451) tau PET in frontotemporal dementia syndromes
por: Tsai, Richard M., et al.
Publicado: (2019)

[(18)F]RO948 tau positron emission tomography in genetic and sporadic frontotemporal dementia syndromes
por: Santillo, Alexander F., et al.
Publicado: (2022)

Head-to-head comparison of relative cerebral blood flow derived from dynamic [(18)F]florbetapir and [(18)F]flortaucipir PET in subjects with subjective cognitive decline
por: Tuncel, Hayel, et al.
Publicado: (2023)

A Routine PET/CT Protocol with Streamlined Calculations for Assessing Cardiac Amyloidosis Using (18)F-Florbetapir
por: Osborne, Dustin R., et al.
Publicado: (2015)

Reference tissue normalization in longitudinal (18)F-florbetapir positron emission tomography of late mild cognitive impairment
por: Shokouhi, Sepideh, et al.
Publicado: (2016)

Non-invasive Standardised Uptake Value for Verification of the Use of Previously Validated Reference Region for [(18)F]Flortaucipir and [(18)F]Florbetapir Brain PET Studies
por: de Vries, Bart M., et al.
Publicado: (2021)

Clinical impact of amyloid PET using (18)F-florbetapir in patients with cognitive impairment and suspected Alzheimer’s disease: a multicenter study
por: Matsuda, Hiroshi, et al.
Publicado: (2022)

PET imaging of amyloid with Florbetapir F 18 and PET imaging of dopamine degeneration with (18)F-AV-133 (florbenazine) in patients with Alzheimer’s disease and Lewy body disorders
por: Siderowf, Andrew, et al.
Publicado: (2014)

Partial Volume Correction Increases the Sensitivity of 18F-Florbetapir-Positron Emission Tomography for the Detection of Early Stage Amyloidosis
por: Teipel, Stefan J., et al.
Publicado: (2021)

Defining the presymptomatic phase of frontotemporal dementia
por: Russell, Lucy L., et al.
Publicado: (2023)

Classification of negative and positive (18)F-florbetapir brain PET studies in subjective cognitive decline patients using a convolutional neural network
por: de Vries, Bart Marius, et al.
Publicado: (2020)

(18)F-florbetapir PET/MRI for quantitatively monitoring myelin loss and recovery in patients with multiple sclerosis: A longitudinal study
por: Zhang, Min, et al.
Publicado: (2021)

[(18)F]AV‐1451 PET in behavioral variant frontotemporal dementia due to MAPT mutation
por: Bevan Jones, W. Richard, et al.
Publicado: (2016)

[18F]FDG-PET in a case of right temporal lobe variant of frontotemporal dementia
por: de Brito, Marcelo Houat, et al.
Publicado: (2019)

[18F]FDDNP performed better than [18F] Florbetapir to distinguish transthyretin cardiac amyloidosis (TTR-CA) patients from healthy controls: an ex vivo study
por: Dupont, Anne-Claire, et al.
Publicado: (2015)

Development of software for measuring brain amyloid accumulation using (18)F‐florbetapir PET and calculating global Centiloid scale and regional Z‐score values
por: Matsuda, Hiroshi, et al.
Publicado: (2023)

Frontotemporal dementia
por: Warren, Jason D, et al.
Publicado: (2013)

[(18)F]AV‐1451 binding is increased in frontotemporal dementia due to C9orf72 expansion
por: Bevan‐Jones, Richard W., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_d2bj65gj70dv5hfrav33lvh0o5